Dementia signs, symptoms may be different for Latinos, researchers say
By
Alicia Lasek
May 27, 2021
Cultural practices and disease processes may explain why Latino adults with dementia experience faster functional decline and higher rates of depression and anxiety, investigators say.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Specialty care is out of reach for most dementia patients: study
By
Alicia Lasek
Sep 04, 2019
Most dementia patients do not receive diagnosis or care from specialists, a new study has found. An “unspecified dementia” diagnosis is common.
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.
Hurricanes hastened the deaths of adults with dementia, study finds
By
Alicia Lasek
Mar 08, 2023
People with Alzheimer’s and related dementias (ADRD) had higher mortality rates in U.S. counties that had recently experienced a hurricane disaster, investigators report.
Brooks-LaSure: Medicare poised to re-evaluate coverage of new Alzheimer’s drugs
By
Alicia Lasek
Dec 12, 2022
In a Milken Institute summit session, the CMS administrator said that Medicare’s door is open to evaluating new data on emerging Alzheimer’s drug candidates.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...